Compare C.H. Robinson Worldwide, Inc. (CHRW) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
C.H. Robinson Worldwide, Inc. vs Pfizer Inc — how do they compare? C.H. Robinson Worldwide, Inc. trades at $147.42 (market cap $17.14B), while Pfizer Inc trades at $26.39 (market cap $149.96B). The key difference: Pfizer Inc is far larger — about 8.7× C.H. Robinson Worldwide, Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.54%). Which is the better fit depends on your goals.
| CHRW | PFE | |
|---|---|---|
Market Cap | $17.14B | $149.96B |
Sector | Industrials | Health |
52-Week High | $209.42 | $28.56 |
52-Week Low | $120.99 | $23.60 |
Enterprise Value | $18.96B | $201.45B |
Dividend Yield | 1.72% | 6.54% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CHRW trades at $146.75, down 1.04% today, amid a bearish technical signal. Recent earnings beats, including Q2 2026 EPS of $1.61 versus $1.53 expected, highlight operational strength. The company maintains a solid dividend, with a $0.63 payment declared for October 2026. Revenue declined to $16.23B in 2025, but net income margin improved to 3.73%. Analyst consensus is bullish with a $193 price target, though technical indicators show selling pressure near key support at $143.
The outlook is mixed: strong profitability and analyst support suggest upside, but technical weakness and a pending legal appeal pose near-term risks. Earnings growth from pricing and efficiency gains remains the key catalyst, while market volatility and freight demand fluctuations are headwinds for investors.
Pfizer (PFE) trades at $26.62, down 1.59% with a bullish technical signal. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analyst consensus is mixed with 38% buy ratings and a $27.86 price target. Recent news highlights Pfizer's pipeline developments in oncology and obesity treatments, positioning for future growth despite patent cliff concerns.
Pfizer presents a value opportunity with defensive cash flows and dividend yield, but faces patent expiration risks and competitive pressures. The stock trades below analyst targets with strong institutional support, though margin compression and pipeline execution remain key watchpoints for investors seeking pharmaceutical exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About C.H. Robinson Worldwide, Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (57% of 2021 net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm also operates a large air and ocean forwarding division (34%), which has grown organically and via tuck-in acquisitions. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
Read more on CHRW →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
